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Abstract
Background: Health-related quality of life (HRQoL) is an important outcome measure among HIV infected patients
receiving antiretroviral therapy (ART). When HIV infected patients coinfected with Visceral Leishmaniasis (VL) the
problem become severe because VL accelerates HIV replication and disease progression. The impact of VL on the
quality of life of HIV infected patients has not been studied. In this study in Ethiopia, we compared the quality of
life of HIV infected patients with and without VL.
Methods: A cross-sectional study was conducted from October 2015 to September 2016 in selected health centers
and hospitals, in Northwest Ethiopia. Data on quality of life was collected by trained nurses. The instrument used
to collect the data was the short Amharic version of the World Health Organization Quality of Life for HIV clients
(WHOQoL-HIV). Depression was assessed using the validated version of Kessler scale. Data was entered and
analyzed using SPSS version 20. Descriptive statistics, bivariate and multivariate linear regression model was used
to summarize the results.
Results: A total of 590 study participants were included in the study with response rate of 95%. Of the 590
patients included in our study 125 (21%) were HIV-VL coinfection. HIV-VL coinfected patients had a lower quality
of life in all the domains as compared to HIV patients without VL. Depression was consistently and strongly
associated with all the quality of life domains of both groups. Also, in HIV infected patients a longer duration in
ART was associated with higher HRQoL domains except for the spiritual and level of independence domains.
With regard to HIV-VL coinfected patients, a longer duration in ART was associated with psychological, spiritual
and level of independence domains of HRQoL. Demographics, clinical, and treatment characteristics resulted few
significant associations with HRQoL domains of both groups.
Conclusion: HIV-VL coinfected patients had a poor quality of life in all the domains of the WHOQoL-HIV instrument.
Depression, duration of ART and education were strongly associated with the quality of life. Depression should be
targeted for intervention to improve the quality of life.
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Background
Visceral leishmaniasis (VL; also known as “kala-azar”) is
a systemic parasitic disease caused by the parasite of
Leishmania donovani species complex. It is estimated
about 500,000 new cases of VL occur annually [1]. VL is
characterized by irregular bouts of fever, substantial
weight loss, swelling of the spleen and liver, and anemia
(which may be serious). If the disease is not treated, the
fatality rate in developing countries can be as high as
100% within 2 years [2]. VL accelerates HIV replication
and disease progression, mainly by chronic immune
stimulation [3].
In India and particularly in Africa, both HIV and VL in-
fection (hereafter, “HIV-VL coinfection”) is emerging. The
AIDS pandemic has expanded to rural areas where VL is
endemic, with cases of HIV-VL coinfection reported in 35
countries [4, 5], among which Ethiopia carries the greatest
burden. The prevalence of HIV and HIV-VL coinfection
in Ethiopia is 1.1% [6] and 17.75% [7] respectively.
The advent of antiretroviral therapy (ART) and its
widespread availability in many settings has reduced the
mortality rate among people living with HIV/AIDS
(PLHA) [8]. As longevity of PLHA improves as a result
of ART, improvement of quality of life (QoL) of these
patients has become an important issue for researchers
and policy makers [9]. Health related quality of life
(HRQoL) is a multidimensional concept that includes
global health perspectives, symptom status, functional
status, biological and physical variables, individual and
environmental characteristics and general health per-
ception [10].
According to the World Health Organization (WHO),
QoL is defined as an individuals’ perception of their
position in life in the context of the culture and value
systems in which they live and in relation to their goals,
expectations, standards and concerns [9]. This definition
considers individuals’ satisfaction on their physical,
psychological, social relationships, environment, and
spiritual aspects of their life [11].
Quality of life is affected by several clinical and socio-
demographic factors. Some of the factors that predict
QoL were baseline CD4 lymphocyte count [12, 13], time
since HIV diagnosis [12], poor social support [14], de-
pression [15–18], unemployment [19], older age [20]
and being female [21].
Many studies have provided important information on
the correlates of HRQoL during HIV infection. Many
studies have documented significant improvements in
QoL during ART [20, 22, 23]. There is however know-
ledge gap on the HRQoL of HIV-VL coinfection as a
treatment outcome. Therefore, the objective of the
present study was to assess the level of HRQoL and its
predictors and/ or correlates among HIV infected adults
with and without VL.
Methods
Study design
Facility based cross-sectional study design was employed
to assess the level of HRQoL and its predictors and/or
correlates among HIV infected adults with and without
VL who visited the health facilities in Northwest Ethiopia.
Study settings and population
From the VL treatment centers found in the Northwest
Ethiopia, three hospitals and one health center were se-
lected purposely considering the availability of invasive
VL diagnostic methods such as demonstration of para-
site from spleen/lymph node aspiration or positive
serology test if the patient has no VL history. In addition
to VL diagnostic method, we also considered the avail-
ability of Fluorescence Activate Cell Sorting (FACS)
count machine for CD4 count and CBC (complete blood
count) machine. Hospitals and Health centers found in
the study area that fulfilled the above considerations
were considered as clusters (units). Cluster sampling
technique was employed in order to include HIV-VL
coinfected study participants. Therefore, Abdrafi Health
center, Metema Hospital, Humera Hospital, and University
of Gondar Hospital were the four selected clusters. All
HIV-VL coinfection diagnosed patients who visited these
facilities were included in the study. The selected Hospitals
and Health center are the only health facilities that have
well organized VL diagnosis and treatment centers found
in the study area. The excluded health facilities in our
study have not yet started diagnosing and treating VL pa-
tients. If HIV-VL coinfected patients visited these health
facilities then they will be referred to one of the selected
health facilities.
The study was carried out at four different sites in
Northwest Ethiopia. The first site was Abdrafi inpatient
kala-azar treatment center located in Abdrafi; at this
health center medical services are provided for patients
with leishmaniasis, HIV-VL coinfection and snake bite.
The second site was Kala-azar Treatment and Research
Center in the University of Gondar Hospital located in
Gondar; at this center both outpatient and inpatient
medical services are provided for patients with leish-
maniasis and HIV-VL coinfection in addition to the
comprehensive medical service from other units of the
University of Gondar Hospital. The third site was Kahsay
Aberra Hospital located in Humera kala-azar treatment
center; at this center both outpatient and inpatient medi-
cal services are provided for patients with leishmaniasis,
HIV-VL coinfection and many other hospital level ser-
vices. The fourth site was Metema Hospital located in
Metema kala-azar treatment center; at this center both
outpatient and inpatient medical services are provided for
patients with leishmaniasis, HIV-VL coinfection and many
other hospital level services.
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Sample size for the two groups was determined using
WINPEPI (Window program for Epidemiologist) [24]. In
a recent study, the mean score of general QoL among
HIV infected patients who were taking highly active anti-
retroviral therapy in Jimma hospital was 87 [25]. Due to
absence of data, we assumed HIV-VL coinfected patients
would have a 5% lower mean score of general health as
compared to HIV patients. With a power of 80%, 95% CI,
a 1:3 ratio of HIV-VL coinfected patients versus HIV pa-
tients, and a 10% for non-response rate, the sample size
was 620 (155 coinfected patients and 465 HIV patients).
The study populations were all HIV-VL coinfected and
HIV infected patients who were attending their treat-
ment in the treatment facilities found in the Northwest
Ethiopia. The study period was from October, 2015 to
September, 2016. During the study period, all new VL
infected patients were identified and then they were
screened for HIV infection. Only HIV-VL coinfected pa-
tients who were in the intensive phase of anti-VL treat-
ment during the study period were included. For each
HIV-VL coinfected patient, 3 HIV infected patients
without VL were selected using simple random sampling
technique. Participants who were mentally incompetent,
age < 15 years, the presence of opportunistic infections
or a known chronic illness like diabetic mellitus and
hypertension were excluded from the study.
Measurements
Diagnosis of VL was conducted according to the guide-
lines for the diagnosis of leishmaniasis in Ethiopia [26].
The WHO case definition of VL was used as a starting
point; history of fever for > 2 weeks, malaria excluded, in
combination with wasting and either splenomegaly or
lymphadenophaty [27]. A patient whose illness met this
case definition and who had no previous VL treatment
was diagnosed serologically by positive rK39 rapid diag-
nostic test (Diamed-IT-Leish, DiaMed AG) [28]. Patients
with previous VL history underwent splenic or lymph
node aspiration and VL confirmed parasitologicaly. A se-
verely ill patient with a negative rK39 test was aspirated
without delay, So that a diagnosis could be made as
quickly as possible.
Provider-initiated testing and counseling for HIV was
offered to all VL patients. The HIV diagnosis was based
on the national algorithm with two serial positive rapid
test results; The KHB (Shanghai Kehua Bio-engineering
Ltd, 2008, Shanghai, China) HIV test was used to diag-
nose HIV. For positive results, confirmation were done
using STAT-PAK test (chembio diagnostic system Inc,
2008, New York, USA). In case of discrepancy be-
tween the two tests, Uni-Gold™ (Trinity Biotech PLC,
Bray, Ireland) was used as a tie breaker. As VL is
considered a stage IV-defining illness in HIV patients
[27, 29], all patients were given ART as soon as they
were stabilized from their acute illnesses. ART regi-
mens follow the national guidelines: tenofovir-
lamivudine-efavirenz; zidovudine-lamivudine-efavirenz;
or zidovudine-lamivudine-nevirapine [30]. Second-line
ART consists of protease inhibitor-based combination
regimens.
QoL was measured at baseline through face to face in-
terviews using the short amharic version of the World
Health Organization QoL Instrument for HIV infected
patients (WHOQoL HIV-Brief ) [31]. This QoL instru-
ment has been described in TB/HIV coinfection and
its impact on quality of life article [16]. In brief, it con-
sisted of 31 Likert scale questions in 6 domains of
QoL: physical health (4 items); psychological wellbeing
(5 items); social relationship (4 items); environmental
health (8 items); level of independence (4 items) and
spiritual health (4 items). There were two questions
about general QoL and perceived general health.
Common Mental Disorder (CMD) was measured
using the Kessler 10 scales [32]. This instrument has 10
questions each asking the respondent how often they ex-
perienced symptoms during the previous 30 days and
containing 5-point Likert scales (1 = never, 2 = a small
part of the time, 3 = some of the time, 4 = most of the
times, 5 = all of the time). The Kessler-10 scale was vali-
dated in Ethiopia and used extensively [33].
Data on demographic factors, clinical and treatment
related factors were collected by using structured and
pre-tested questionnaire which was developed by the in-
vestigators. The structured questionnaire was prepared
in English version and translated into Amharic (local
language) and again back to English to confirm the cor-
rectness of the translation and for analysis purpose. The
data collectors were 4 nurses and we also recruited 4
physicians as supervisors for the data collectors.
Data analysis
Each completed questionnaire was checked visually for
completeness before fed to computer. The data was en-
tered into SPSS version 21, data clean up and cross-
checking was done and it was analyzed by using SPSS
version 20. Domain scores in the WHOQoL-HIV-Brief
were scaled in positive direction with higher score de-
noting good quality of life. Negative questions like pain
and discomfort were recorded so that higher scores re-
flect better QoL. Mean scores of items within each
domain was used to calculate the domain score. Mean
scores were then multiplied by 4 to make domain scores
comparable with the scores used in the World Health
Organization QoL (WHOQoL-100). We used T-test and
F-test to compare means between groups.
Independent variables which were associated with each
of the six HRQoL domains were first identified using bi-
variate linear regression analysis. Then all the variables
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Table 1 Socio-demographic and clinical characteristics of the study population in Northwest Ethiopia
Variables HIV-VL coinfected patients (N = 125)
Number (%)
HIV infected patients (N = 465)
Number (%)
P-value
Age in Years 0.001
15–24 1 (0.8%) 22 (4.7%)
25–34 72 (57.6%) 177 (38.1%)
≥ 35 52 (41.6%) 266 (57.2%)
Sex 0.001
Male 121 (96.8%) 178 (38.3%)
Female 4 (3.2%) 287 (61.7%)
Residence 0.001
Urban 85 (68.0%) 438 (94.2%)
Rural 40 (32.0%) 27 (5.8%)
Educational Status 0.001
Uneducated 65.6 (65.6%) 210 (45.2%)
Primary cycle 23 (18.4%) 92 (19.8%)
Secondary and above 20 (16.0%) 163 (35.1%)
Occupation 0.001
Farmer 38 (30.4%) 26 (5.6%)
Daily Labor 65 (52.0%) 74 (15.9%)
Employed 16 (12.8%) 131 (28.2%)
No Job 1 (0.8%) 63 (13.5%)
Merchant 2 (1.6%) 52 (11.2%)
Housewives 3 (2.4%) 119 (25.6%)
Religion 0.481
Christian 112 (89.6%) 426 (91.6%)
Muslim 13 (10.4%) 39 (8.4%)
Ethnicity 0.001
Amhara 82 (65.6%) 404 (86.9%)
Tigray 38 (30.4%) 48 (10.3%)
Others 5 (4.0%) 13 (2.8%)
Marital status 0.001
Single 52 (41.6%) 68 (14.6%)
Married 40 (32.0%) 234 (50.3%)
Separated 10 (8.0%) 44 (9.5%)
Divorced 19 (15.2%) 64 (13.8%)
Widowed 4 (3.2%) 55 (11.8%)
WHO staging 0.001
Stage I - 302 (64.9%)
Stage II - 76 (16.3%)
Stage III - 78 (16.8%)
Stage IV 125 (100%) 9 (1.9%)
On Antiretroviral therapy 0.001
Yes 64 (51.2%) 465 (100%)
No 61 (48.8%)
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that yielded p-values of <0.2 were fitted in the multivari-
ate linear regression model. We checked for violations
of regression model assumptions by inspection of plots
of residuals versus predicted values, outliers and multicol-
linearity. Results of the regression analysis are expressed
in un-standardized coefficient (beta). Beta coefficients are
measured in units of standard deviation and refer to the
average change in the dependent variable for a unit in-
crease in the predictor variable.
Results
Characteristics of the study participants
A total of 590 study participants were included in the study
with response rate of 95%. Of the 590 patients included in
our study 125 (21%) were HIV-VL coinfected. Thirty partic-
ipants refused to participate in the study. The mean age
(±SD) was 34.3 (±7.4) year for HIV-VL coinfected and 36.4
(±8.8) year for HIV infected study participants.
Males and urban residents were more likely to be in-
fected by visceral leishmaniasis (VL) than their counter
parts (p = 0.001). HIV-VL coinfected patients were more
likely to have lower CD4 lymphocyte and observed
hemoglobin (Hb) level than HIV patients (p = 0.001). All
the coinfected patients were WHO stage IV and 65% of
HIV infected patients were stage I. All HIV patients and
51% of the coinfected patients were taking ART during
the study period (Table 1).
Internal consistency of the WHOQOL-HIV
To measure internal consistency, the Cronbach’s alpha
was calculated for each domain of the instrument. Most
domains of the amharic version of the WHOQoL-HIV
had a high value of Cronbach’s alpha (α > 0.7). However,
spiritual health had a lower internal consistency (α = 0.64)
as compared to others (Table 2).
The Kessler scale
The correlation between items in the Kessler scale
ranged from 0.36 to 0.68 with no multicollinearity and
redundancy. The internal consistency of the Kessler
scale was high (Cronbach’s α = 0.88).
Inter domain correlations showed that there were
statistically significant associations between domains.
However, there was no correlation between psycho-
logical health, social relation, and environmental health
with spiritual health. There was a week correlation
between spiritual health and level of independence
(Table 3).
Table 2 Internal consistency of the Amharic version of the
WHOQOL-HIV questionnaire
Domain Coefficient for internal
consistency (Cronbach’s alpha)
Physical 0.82
Psychological 0.88
Social relation 0.73
Environmental 0.88
Level of independence 0.77
Spiritual 0.64
Table 1 Socio-demographic and clinical characteristics of the study population in Northwest Ethiopia (Continued)
CD4 count (mg/dl)
Median (Range) = 340 (from 30 to 1652) 0.001
≤ 100 71 (57.7%) 20 (4.3%)
101–200 38 (30.9%) 47 (10.1%)
≥ 200 14 (11.4%) 398 (85.6%)
Observed Hb level (mg/dl)
Mean (±SD) =12.8 (±2.8) 0.001
< 12.8 120 (96.8) 101 (23.1%)
≥ 12.8 4 (3.2) 336 (76.9%)
Spleen size (cm)
< 15 109 (94.8%) NA
≥ 15 6 (5.2%) NA
Table 3 Correlations between the domains of the Amharic
version of the WHOQOL-HIV questionnaire
Domains PH Psy Soc Env Ind Spir
PH 1
Psy 0.374a 1
Soc 0.303a 0.676a 1
Env 0.344a 0.728a 0.661a 1
Ind 0.570a 0.594a 0.556a 0.586a 1
Spir 0.348a 0.056 0.053 0.093b 0.243a 1
PH Physical health, Psy Psychological health, Soc Social relation, Env Environment,
Ind Level of Independence, Spir Spiritual
aCorrelation is significant at the 0.01 level (2-tailed), bCorrelation is significant
at the 0.05 level (2-tailed)
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We found correlations between the WHOQoL do-
mains and the Kessler scale. Strong correlations was
observed between physical health (correlation coeffi-
cient or r = −0.633, p = 0.001), level of independence
(r = −0.509, p = 0.001) and spiritual health (r = −0.403,
p = 0.001) with Kessler scale. Psychological health,
social relation, and environmental domains had a cor-
relation coefficient of −0.335, −0.295 and −0.350 with
Kessler scale respectively (p-value = 0.001).
Quality of Life
HIV-VL coinfected patients had a lower mean score in
all domains indicating poor quality of life. Mean scores
for physical health, social relationship and environmental
health among coinfected patients were 10.42, 9.71 and
9.66 respectively. The mean (SD) depressive-symptoms
scale score were higher 2.67 (±0.7) for HIV-VL coin-
fected patients than HIV patients1.61 (±0.5) (p = 0.001)
(Table 4).
Predictors of QOL
Tables 5 and 6 show the results of the bivariate and
multivariate linear regression analysis for predictors of
the HRQoL domains respectively. The final multivari-
ate regression model did not suggest multicollinearity
problems.
In the bivariate analysis duration of ART and Kessler
depressive-symptoms were associated with HRQoL
across all the domains for both groups. Observed Hb
level ≥12.8 also strongly associated with physical, psy-
chological, social and environmental domain for HIV
infected group. As clearly indicated in Table 5, the vari-
ables with p-value <0.2 were entered into the multivari-
ate analysis of each HRQoL domains.
A higher level of depressive-symptoms was strongly
and consistently associated with a lower HRQoL across
all the domains of both groups. Also, in HIV infected
patients a longer duration in ART was associated with
higher HRQoL domains except for the spiritual and level
of independence domains. With regard to HIV-VL coin-
fected patients, a longer duration in ART was associated
with psychological, spiritual and level of independence
domains of HRQoL.
Having higher CD4 count (≥201 mg/dl) was associated
with higher HRQoL on psychological and level of inde-
pendence domains of HIV infected patients. Higher CD4
count has no association in all the domains of HRQoL
of HIV-VL coinfected patients.
Being educated in HIV infected patients was associ-
ated with higher HRQoL on psychological, social, level
of independence and environmental domains. There was
no association found between education and HRQoL do-
mains for HIV-VL coinfected patients.
Most demographics, clinical and treatment related
variables were not associated with HRQoL domains or
associated with fewer HRQoL domains for HIV infected
patients. In HIV-VL coinfected patients, no statistically
significant associations were found between HRQoL and
employment, sex, education, marital status, residence,
CD4-cell count and Hb level.
Discussion
In this study we compared the HRQoL of persons with
HIV infection with and without VL. Coinfected patients
had a lower quality of life in all the domains of the
WHOQoL-HIV as compared to people living with HIV
without VL. The concurrent occurrence of these two
diseases in a person can decrease the quality of life by
affecting the physical, social and mental wellbeing. The
reason for this is VL accelerates HIV replication and
disease progression, mainly by chronic immune stimula-
tion [3]. In other studies, it was reported that HIV pa-
tients when coinfected with other disease such as
Tuberculosis (TB) had a lower quality of life as compared
to HIV infected patients without TB coinfection [16].
It is difficult to compare the levels of HRQoL of HIV-
VL coinfected patients in this study with HRQoL of
HIV-TB coinfected patients since the nature and charac-
teristics of these two diseases (TB and VL) are entirely
different. Though, compared to the study conducted
among TB and HIV coinfected patients in East and
Southwest Ethiopia [16], HIV-VL coinfected patients in
our study reported lower levels of HRQoL in all domains
Table 4 Comparison of Quality of life of HIV infected patients with and without Visceral Leishmaniasis in Northwest Ethiopia
Quality of life Domain HIV-VL coinfection (n = 125)
Mean (±SD)
HIV infected patients (n = 465)
Mean (±SD)
P-value
Physical Health 10.42 (±3.5) 17.43 (±2.8) 0.001
Psychological Health 10.68 (±3.6) 12.60 (±3.4) 0.001
Social Health 9.71 (±3.1) 11.44 (±3.4) 0.001
Environmental Health 9.66 (±3.1) 11.53 (±2.9) 0.001
Level of independence 9.46 (±3.2) 13.34 (±2.8) 0.001
Spiritual Health 11.49 (±3.3) 15.06 (±3.4) 0.001
Depressive-symptoms 2.67 (±0.7) 1.61 (±0.5) 0.001
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of HIV-TB coinfected patients. HIV infected patients
without VL in our study also reported lower HRQoL in
all domains except for the physical health domain as
compared to HIV infected patients without TB. This is
not meant strict comparison, however, as patients in this
study coinfected with VL and there may also be addi-
tional differences of perception of personal beliefs.
Nevertheless, our study result of HIV infected patients
without VL is comparable with findings from HRQoL of
HIV infected adults receiving cART in Addis Ababa [17]
and the baseline finding of prospective longitudinal
study done in Northwest Ethiopia [34].
A higher level of depressive-symptoms was most
strongly and consistently associated with a lower HRQoL
across all the domains, both in-terms of the magnitude of
relationship and in the number of HRQoL domains as-
sociated with it in both HIV-VL coinfected and HIV
infected without VL patients. This finding is in line
with previous studies conducted in variety of research
settings [15, 17, 35]. Therefore, this study gives addi-
tional evidence in order to design intervention to allevi-
ate depressive-symptoms in HIV and HIV-VL infected
patients.
A longer duration of cART for HIV infected patients was
independently associated with better HRQoL domains, ex-
cept with the spiritual and level of independence domains.
A longer duration of cART for HIV-VL coinfected patients
was associated with psychological, spiritual and level of in-
dependence domains of HRQoL. In line with this finding,
there was a study conducted by Casado et al. [36] assessed
Table 6 Multivariate linear regression analysis of predictors and/or correlates of HRQoL of HIV infected patients with and without VL
in Northwest Ethiopia
Patient
characteristics
HRQoL domains
Physical domain
(β-coefficient)
Psychological
domain
(β-coefficient)
Social Domain
(β-coefficient)
Spiritual domain
(β-coefficient)
Level of
independence
(β-coefficient)
Environmental
domain
(β-coefficient)
HIV-VL
(n = 125)
HIV
(n = 465)
HIV-VL
(n = 125)
HIV
(n = 465)
HIV-VL
(n = 125)
HIV
(n = 465)
HIV-VL
(n = 125)
HIV
(n = 465)
HIV-VL
(n = 125)
HIV
(n = 465)
HIV-VL
(n = 125)
HIV
(n = 465)
Age −0.083* −0.031*
Sex
Male
Female
Education
Not educated Ref. Ref. Ref. Ref.
Educated 1.432** 1.142** 0.589* 1.378**
Marital status
Married 0.816** 1.415** 0.495*
Not married Ref. Ref. Ref.
Residence
Urban
Rural
CD4 count
< 201 Ref. Ref.
> =201 1.034* 0.843*
Hb level
< 12.8
> =12.8
Duration of ART 0.144** 0.224* 0.232** 0.184** 0.221* 0.258* 0.197**
Kessler depressive
symptoms
−2.118** −2.489** −2.670** −1.220** −1.981** −0.603* −1.887** −1.449** −1.630** −1.724** −2.275** −0.925**
p-value of the
final multivariate
regression model
P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01 P < 0.01
Adjusted-R2 0.239 0.288 0.355 0.148 0.261 0.125 0.232 0.047 0.278 0.150 0.302 0.155
Ref. reference category
*p – value < 0.05; **p – value < 0.01
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longitudinal changes in QOL for three months after begin-
ning cART. There is also another study conducted by Man-
neiner et al., [20], who reported significant improvement in
QoL after 1 to 4 months of treatment with cART, and this
improvement persisted at 12 months. On the other hand,
Wouters et al. [37] reported that additional cART did not
further improve the QoL of patients who had received
cART for less than 6 months at baseline.
Among the socio-demographic variables, older age
was a significant predictor for poor physical health do-
main in both HIV-VL and HIV infected patients. This
finding is in line with previous study results [17]. This
might be because of physical functioning deteriorates as
a result of aging or age related co-morbidities [38]. Being
married HIV infected patients without VL was associ-
ated with higher HRQoL for physical, social and level of
independence domains. There is a study [39] which have
consistent finding with our study. It is believed that the
physical, emotional and social support received from
their partners likely led to improve QoL. There is evi-
dence that showed support from outside the family can-
not replace for what is missing in the family [39]. In
contrast, there is also evidence on marital status had no
significant association with any of the domains of
HRQoL [40].
Educated HIV infected patients as compared to not
educated was strongly associated with higher HRQoL on
psychological, social, level of independence and environ-
mental domains. This finding is in line with other coun-
try study among patients with HIV, the less educated
had a lower quality of life [41]. There was no association
found between education and all the domains of HRQoL
for HIV-VL coinfected patients. Possibly, this might be
explained by the small sample size or lower percentage
of (i.e., 21%) of patients with evidence of VL at or after
start of cART.
Having higher CD4 count (≥201 mg/dl) was associ-
ated with higher HRQoL on psychological and level of
independence domains of HIV infected patients. This
finding is in line with the previous study [13]. In con-
trast to these findings, we didn’t find a significant rela-
tionship between most of the domains of HRQoL of
HIV infected patients and all the domains of HRQoL of
HIV-VL coinfected patients and CD4-cell count. This
finding is also in line with the previous studies done in
Ethiopia [16, 17].
In contrast with other studies, we couldn’t find an as-
sociation between WHO staging, employment, social
support, source of income and other socio-demographic
factors [16, 17, 41].
The findings of this study should be interpreted
with some limitation. Being a cross-sectional study,
causal inference cannot be made between HRQoL and
independent variables especially the relationship between
HRQoL and depression is complex and bidirectional. VL
might induce depression but we didn’t include group of
patients with VL alone to complement the relationship.
Administering the questionnaire through face to face
interview may have resulted socially desirable response.
Therefore, social desirable bias might be introduced.
Conclusion
HIV-VL coinfected patients had a poor quality of life in
all the domains of the WHOQOL-HIV instrument.
Depression, duration of ART and education were
strongly associated with the quality of life. The govern-
mental and non-governmental organizations working in
VL control programs should design strategies to improve
the quality of life of HIV-VL coinfected patients. Depres-
sion should be targeted for intervention to improve the
quality of life. To increase adherence of cART and quality
of life, patients should be counseled and educated.
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